Verrica Doses First U.S. and Japanese Patients in Phase 3 COVE-3 Trial of YCANTH for Common Warts
核心洞察
Verrica Pharmaceuticals announced the first U.S. patient has been dosed in the COVE-3 pivotal Phase 3 trial evaluating YCANTH (VP-102) (搜索) for the treatment of common warts (搜索).
Development partner Torii Pharmaceutical (搜索) simultaneously dosed the first Japanese patient in the same COVE-3 study, marking a key milestone in the global Phase 3 program.
Common warts (搜索) affect an estimated 22 million people in the U.S. alone with no FDA-approved therapies, representing one of the largest unmet needs in dermatology.
Verrica Pharmaceuticals Inc. announced on June 22, 2026 that the first U.S. patient has been dosed in the COVE-3 clinical trial, the second pivotal study in its global Phase 3 program evaluating YCANTH (VP-102) (搜索) for the treatment of common warts (搜索). Concurrently, Verrica's Japanese development partner, Torii Pharmaceutical (搜索) Co. Ltd., a wholly-owned subsidiary of Shionogi & Co., Ltd., confirmed that the first Japanese patient in the COVE-3 study was dosed the prior week.
"We are excited to get the COVE-3 clinical trial started with the enrollment of our first patient in the U.S. and would like to congratulate our development partner, Torii Pharmaceutical (搜索), for also reaching this important and exciting clinical milestone for YCANTH in Japan," said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. "Throughout our joint efforts to develop YCANTH for the global markets, Torii has served as an outstanding and supportive development partner, and the advancement of YCANTH into both of the planned pivotal Phase 3 studies reflects our companies' steadfast commitment to address a significant unmet need for the millions of individuals, including an estimated 22 million people in the U.S. alone, impacted by common warts (搜索) each year."
Trial Design and Program Structure
The Phase 3 program comprises two double-blind, randomized, vehicle-controlled studies designed to evaluate the efficacy and safety of VP-102 (known as TO-208 in Japan) when applied once every 21 days for a total of up to four applications in patients aged 2 years and older with common warts (搜索). The COVE-2 study is enrolling patients exclusively in the U.S., while the COVE-3 study is enrolling patients in both the U.S. and Japan. Based on the results of the Phase 3 program, Verrica and Torii intend to seek marketing approval in the U.S. and Japan, respectively.
Dr. Rieger noted that the program has made substantial enrollment progress: "As we reported last month, we have achieved over 50% of the current targeted enrollment in the first trial in this Phase 3 program (COVE-2) in the U.S. and have also been enrolling U.S. patients in the long-term follow-up study (COVE-4)."
Phase 2 Foundation and Clinical Evidence
The initiation of the global Phase 3 program was based on positive results from the Phase 2 COVE-1 clinical trial. COVE-1 was an open-label study that evaluated the safety and efficacy of VP-102 in two cohorts of subjects with up to six warts. The primary efficacy analysis was conducted at Day 84, with an additional period of follow-up through Day 147. Topline analysis included data from the assessment of warts at study visits over 12 weeks.
Results demonstrated that 51% of subjects (18 of 35) treated with VP-102 in Cohort 2 achieved complete clearance of all treatable warts at Day 84. Adverse events were primarily expected local cutaneous reactions, and no serious adverse events were observed.
Market Opportunity and Unmet Need
Common warts (搜索) represent one of the largest unmet needs in dermatology, with a prevalence of approximately 22 million patients in the U.S. alone and no FDA-approved therapies currently available. Verrica believes this indication could represent a multibillion-dollar commercial opportunity. In the United States, approximately 50% of patients who seek treatment for common warts are children.
If YCANTH is successfully developed, approved, and commercialized for common warts (搜索), Verrica anticipates a high degree of call point overlap and marketing synergies with its existing promotion of YCANTH for the treatment of molluscum contagiosum (搜索).
Financial and Partnership Arrangements
Under the collaboration agreement, Torii will split the costs of the global Phase 3 program with Verrica on a 50/50 basis and will fund the first $40 million of trial costs, representing approximately 90% of the current trial budget. Verrica's portion is expected to be paid out of future milestones and royalties arising from sales of YCANTH in Japan. Verrica maintains ownership of global rights to YCANTH for all indications in all territories outside of Japan, including common warts (搜索).
About YCANTH
YCANTH is a proprietary drug-device combination product containing a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration. It is the first and only healthcare professional-administered product approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum (搜索), a highly contagious skin disease affecting an estimated six million people in the United States, primarily children. YCANTH is also approved for molluscum contagiosum in Japan. Approximately 250 million lives are eligible to receive YCANTH covered by insurance in the U.S.